Skip to main content

Table 1 Clinical, anthropometrics, laboratory and polymorphism data of the studied group

From: ADIPOQ and IL6 variants are associated with a pro-inflammatory status in obeses with cardiometabolic dysfunction

Variable

Normoweight (51)

Overweight (53)

Obese (145)

P-value

Age, years

46.6. ± 8.3

47.9 ± 6.9

48.7 ± 9.2

0.323

Ethnics [White], %

78.4 (40)

69.8 (37)

71.0(103)

0.539

Woman, %

92.2 (47)

79.2 (42)

75.2 (109)

0.035

Menopause,%

10.6 (5)

26.2 (11)

33.9 (37)

0.011

Hypertension, %

13.7 (7)

28.3 (15)

45.5 (66)

<0.001

Type 2 diabetes, %

33.3 (17)

41.5 (22)

55.7 (99)

<0.001

Family history of CAD

11.7 (6)

20.8 (11)

17.9 (26)

0.455

Tobacco smoking,%

17.6 (9)

23.2 (10)

13.1 (19)

0.527

Alcohol consumption, %

2.0 (1)

3.8 (2)

3.4 (5)

0.845

Physical exercise practice,%

50.9 (26)

50.9 (27)

29.6 (43)

0.003

Body mass index, kg/m2

22.6 ± 1.7a

27.4 ± 1.4b

35.1 ± 4.2c

<0.001

Waist circumference, cm

73.9 ± 8.7a

86.8 ± 9.4b

104.1 ± 11.0c

<0.001

Waist- hip ratio

0.78 ± 0.07a

0.84 ± 0.08b

0.90 ± 0.10 c

<0.001

Body fat, %

30.9 ± 4.7a

33.9 ± 6.4b

38.5 ± 5.0c

<0.001

BMR, kcal

1272 ± 240a

1501 ± 295b

1742 ± 280c

<0.001

Leptin, ng/mL

13.6 ± 8.1a

15.7 ± 12.0a,b

22.9 ± 19.2b

0.012

sLEPR, ng/mL

23.8 ± 12.4a

19.1 ± 13.5a,b

20.0 ± 24.0b

0.011

Adiponectin, μg/mL

24.6 ± 23.2

17.7 ± 23.0

27.2 ± 26.4

0.070

Glucose, mg/dL

92 ± 9a

102 ± 26a,b

106 ± 29b

<0.001

HbA1c, %

5.5 ± 0.4a

6.0 ± 1.3a,b

6.0 ± 1.4b

0.005

Insulin, mU/L

6.6 ± 4.3a

9.7 ± 6.1b

21.3 ± 12.2b

<0.001

HOMA-β

23.0 ± 18.2a

33.3 ± 24.5b

68.7 ± 37.2b

<0.001

HOMA-IR

1.5 ± 1.0a

2.4 ± 1.5b

5.9 ± 4.8b

<0.001

Total cholesterol, mg/dL

194 ± 36

203 ± 37

209 ± 40

0.077

HDL ccholesterol, mg/dL

65 ± 19a

55 ± 17b

51 ± 12b

<0.001

LDL cholesterol, mg/dL

113 ± 32a

125 ± 32a,b

128 ± 32b

0.016

VLDL cholesterol, mg/dL

16 ± 8a

23 ± 10b

30 ± 18c

<0.001

Triglycerids, mg/dL

79 ± 38a

114 ± 53b

150 ± 88c

<0.001

Apolipoprotein AI, mg/dL

160 ± 40a

152 ± 36a,b

146 ± 31b

0.009

Apolipoprotein B, mg/dL

89 ± 28a

109 ± 38b

101 ± 28b

0.004

Fibrinogen, mg/dL

341 (304–374)a

350 (319–409)a,b

374 (328–446)b

<0.001

PAI-1, ng/mL

62.5 (44.7-76.1)a

63.6 (51.0-95.4)a

96.1(60.0-150.6)b

<0.001

IL-6, pg/mL

0.08 (0.07-0.09)a

0.09 (0.08-0.55)a,b

0.56 (0.28-1.6)c

<0.001

IL-1β, pg/dL

5.0 (4.0-5.6)a

5.9 (4.0-6.1)a,b

18.0 (15.0-51.5)c

<0.001

hsCRP, mg/L

0.14 (0.05-0.58)a

0.49 (0.08-1.17)a,b

1.72 (0.26-5.69)c

<0.001

TNFα, pg/mL

0.56 (0.09-1.25)a

0.71 (0.32-2.85)a,b

3.17 (1.45-6.05)c

<0.001

Minor Allele Frequency, %

    

ADIPOQ 45 T > G (rs2241766)

19.6

22.6

21.7

0.858

IL6 -174G > C (rs1800795)

26.4

37.7

31.0

0.209

  1. Number of individuals is in parenthesis. Results are shown as mean ± SD or median (interquartile range) and compared by Anova (Multiple comparisons by Holm-Sidak method) or Kruskal Wallis (Dunn’s Method). Different letters indicate differences between mean values. Categorical variables were compared by chi-square. BMR: basal metabolic rate; CAD: coronary artery disease; HDL: high-density lipoprotein; hsCRP: high sensitive C reactive protein; LDL: low-density lipoprotein; PAI-1: plasminogen activator inhibitor-1; IL-6: interleukin 6; IL-1β: interleukin 1beta; sLEPR: soluble leptin receptor; TNFα: tumor necrosis factor alpha; VLDL: very low-density lipoprotein.
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us